Corporate ActionAug 13, 2026, 10:24 PM
Zentalis Prices Public Offering of 23M Shares at $3.50/Share for $80.5M
AI Summary
Zentalis Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at $3.50 per share. The offering is expected to generate approximately $80.5 million in gross proceeds for the company. Zentalis plans to use the net proceeds, along with existing cash, to fund clinical trials, preclinical studies, regulatory filings, manufacturing, and pre-commercial activities for its programs, as well as for general corporate purposes.
Key Highlights
- Zentalis priced an underwritten public offering of 23,000,000 shares of common stock.
- The public offering price is $3.50 per share.
- Total gross proceeds are expected to be approximately $80.5 million.
- Underwriters have a 30-day option to purchase up to an additional 3,450,000 shares.
- Net proceeds will fund clinical trials, preclinical studies, regulatory filings, and manufacturing.
- Proceeds will also be used for pre-commercial activities, capital expenditures, and general corporate purposes.
- The offering is expected to close on August 17, 2026.
Price Impact
More from ZNTL